micro-community-banner
  • Saved

3yr
Bempedoic Acid's Use as an Adjunct in Lowering Low-Density Lipoprotein Cholesterol in Patients With Coronary Artery Disease: A Systematic Review

Bempedoic Acid's Use as an Adjunct in Lowering Low-Density Lipoprotein Cholesterol in Patients With Coronary Artery Disease: A Systematic Review

Source : https://www.cureus.com/articles/106347-bempedoic-acids-use-as-an-adjunct-in-lowering-low-density-lipoprotein-cholesterol-in-patients-with-coronary-artery-disease-a-systematic-review

Coronary artery disease (CAD) is one of the leading causes of death worldwide. Atherosclerosis begins in childhood as fatty streaks, progresses with age, and lifestyle influences the progression of atherosclerotic...



Relevance: The CLEAR Outcomes trial, scheduled to be completed by December 2022, will provide further information on BDA. BDA appears to be a promising alternative to currently available secondary lipid-lowering agents.

  • Saved

3yr
Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins - PubMed

Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36316612/

doi: 10.1007/s40256-022-00552-7. Online ahead of print. 1 Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Mail Stop C238, 12850 E. Montview Blvd, Aurora, CO, 80045, USA. [email protected]. 2...



Conclusions: Further LDL-C reductions through the addition of BA EZE FDC to maximally tolerated statins are predicted to reduce major adverse cardiovascular events compared with the addition of EZE. Benefits are potentially greater among those with higher starting LDL-C.

  • 3yr
    Key Points • Source: American Journal of Cardiovascular Drugs • Conclusion: “Further LDL-C reductions through the addition of BA+EZE FDC [fixed-dose combination of bempedoic acid plus ezetimibe] to maximally tolerated statins are predicted Show More
  • Saved

3yr
Highlights from the 2022 American Heart Association Scientific Sessions

The American Heart Association (AHA) Scientific Sessions 2022 featured the latest practice-changing research in cardiovascular health. The hybrid AHA meeting took place virtually and in person from Nov. 5 to 7, 2022, at the McCormick Place Convention Center in Chicago.

Above, we summarize some of the presentations that caught our eye at the conference on topics like treating chronic limb-threatening ischemia, congenital heart defects, and more. Stay tuned for our post conference wrap-up report coming soon.

  • Saved

3yr
Highlights from the 2022 American Heart Association Scientific Sessions

The American Heart Association (AHA) Scientific Sessions 2022 featured the latest practice-changing research in cardiovascular health. The hybrid AHA meeting took place virtually and in person from Nov. 5 to 7, 2022, at the McCormick Place Convention Center in Chicago.



Above, we summarize some of the presentations that caught our eye at the conference on topics like treating chronic limb-threatening ischemia, congenital heart defects, and more. Stay tuned for our post conference wrap-up report coming soon.

 

  • Saved

3yr
Highlights from the 2022 American Heart Association Scientific Sessions

The American Heart Association (AHA) Scientific Sessions 2022 featured the latest practice-changing research in cardiovascular health. The hybrid AHA meeting took place virtually and in person from Nov. 5 to 7, 2022, at the McCormick Place Convention Center in Chicago.



Above, we summarize some of the presentations that caught our eye at the conference on topics like treating chronic limb-threatening ischemia, congenital heart defects, and more. Stay tuned for our post conference wrap-up report coming soon.